PURR.AI

Company: 

PURR.AI is at the forefront of merging Artificial Intelligence (AI) with biology to address one of the most pressing issues of our time: aging and its related neurological disorders. Since its inception in Portugal on 17 August 2023, PURR.AI has adhered to stringent healthcare and technology standards, ensuring ethical and accountable operations. PURR.AI is an independent company, fully owned and controlled by its three co-founders, and embodies a collaborative ethos driven by a team of experts in AI, biology, neuroscience, and business, fueling its growth and success. We are not just another tech company; we are a group of innovators dedicated to making a real difference in healthcare.

Mission: 

As people live longer, they experience more age-related neurological disorders. To address this, we need to understand the intricate workings of brain targets, specifically focusing on G-Protein Coupled Receptors (GPCRs). These receptors are intricate switches in the brain that are crucial for the nervous system. However, the complexity of these GPCRs, especially how they pair up (or 'dimerize') and their accessibility to drugs, poses a significant challenge. That is where PURR.AI steps in, with our AGELESS platform, which includes AGELESS.DB and AGELESS.MAP, designed to unlock new possibilities for brain health. Moreover, we address the need for targeted Protein-Protein Interaction (PPI) modulators capable of intervening in protein pairs and crossing the Blood-Brain Barrier (BBB), two critical factors in the current high failure rates of treatments for neurological disorders.

Value Proposition:

• Understanding Aging and the Brain: We delve deeply into the complex relationship between aging and brain health, bringing new insights to tackle neurological disorders.

1. Advanced AI Technology: Our cutting-edge AI tools leverage Natural Language Processing (NLP), Machine-Learning (ML), and Deep-Learning (DL) to predict and analyze changes in brain targets, leading to better understanding and treatment.
2. Data-driven Decision Making: AGELESS integrates diverse data for comprehensive biological profiling and mechanistic insights. We gather and analyze a wealth of information, from genetics to protein structures, to create a detailed map of brain diseases.
3. GPCR Expertise: We specialize in GPCR-targeted drug development, which is crucial for age-related neurological diseases and already constitutes nearly 40% of all available drugs.
4. Customizability: Our modular platform meets various client needs, enhancing usability and interpretability. AGELESS is truly a versatile tool for drug development.
5. Speed and Accuracy: AI-driven processes ensure swift and accurate drug development and reduce costs.
6. Revolutionary Leap: We are set to revolutionize the discovery and development of drugs for brain health, potentially improving millions of lives. Moreover, AGELESS is poised to transform the drug discovery pipeline of the pharmaceutical industry.

Enhancing Treatment Strategies:

Recognizing that complex neurological disorders often require multi-faceted treatment approaches, PURR.AI is pioneering the use of two approaches: drug-drug combinations or drug-like peptides or peptide mimics. This strategy allows us to target multiple disease aspects simultaneously, enhancing treatment effectiveness, and personalizing medicine to meet individual patient needs. 

Addressing Key Challenges:

• Making Brain Signals Clearer: We are working to understand how GPCRs work in pairs and affect brain signaling, which could lead to breakthrough treatments.
• Creating Targeted Brain Therapies: We design innovative peptide-like drugs and drug combinations that can precisely target these GPCR pairs, thereby offering more effective and safer treatments for brain disorders.

• Overcoming Brain Barriers: One of our innovative projects involves designing specialized delivery methods to the brain, a crucial step in effectively treating brain diseases.

   

AGELESS Advantage:

Our AGELESS platform comprises more than just proprietary databases and algorithms; it is a gateway for pioneering treatments for brain health. It is designed to be user-friendly and accessible, pushing the boundaries of GPCR pharmacology towards “biased dimers”.